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Objective: The main objective of this study was to investigate thermosensitive Pluronic® F-127 
(PF-127) hydrogel for the modified release of a potent alcohol and opioid antagonist, naltrexone 
(NTX) hydrochloride, in a subcutaneous injectable dosage form.
Methods: The NTX hydrogels were prepared by the cold method, and the in vitro release 
profiles of various formulations were evaluated at 37°C using the Franz diffusion cell system. 
We examined the different PF-127 concentrations, pH of solution, and inorganic salts on drug 
release from these gels.
Results: The data showed an increase in PF-127 content from 20% to 35%, resulting in a decrease in 
the rate of NTX release. Among the formulations prepared in different pH solutions, pH 7.4 produced 
the slowest drug release rate. The addition of inorganic salts had no significant effect on drug release. 
However, these factors appeared to have limited effects on drug release rate. Therefore, to achieve 
a sustained-release formulation, a NTX and triacetyl β-cyclodextrin (TAβCD) complex was evalu-
ated. The binary systems of NTX/TAβCD in different molar ratios were prepared by the kneading 
method, and complex formation was demonstrated by differential scanning calorimetry.
Conclusion: The results of the current in vitro study indicate that PF-127 gel formulations 
containing drug complexes with hydrophobic cyclodextrin could be useful for the preparation 
of a controlled delivery system of water-soluble drugs such as NTX, for a period of more than 
140 hours.
Keywords: naltrexone, thermosensitive hydrogel, prolonged release, triacetyl β-cyclodextrin, 
kneading method
Introduction
The usefulness of naltrexone in opioid dependence is limited by low retention during 
treatment. Naltrexone (NTX) temporarily blocks substance intake and does not affect 
craving. Sustained-release preparations of NTX have shown rather promising results. The 
development of new injectable drug delivery systems has received considerable attention 
over the past few years.1–3 Our research interest has been sparked by the advantages of 
these delivery systems, which include ease of application, prolonged delivery periods, 
decreased drug dosage with concurrent reduction in undesirable side effects common to 
most forms of systemic delivery, and improved patient compliance and comfort.4
PF-127, or poloxamer 407 (Pluronic®) is a commercially available polyoxyethylene-
propylene copolymer, of general formula E106 P70 E106, with an average molar mass 
of 13,000.5,6 It contains approximately 70% ethylene oxide, which accounts for its 
hydrophilicity.7–9 This thermosensitive amphiphilic polymer has been widely used in the 
biomedical field due to its low toxicity, excellent compatibility with other chemicals, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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and high solubilizing capacity for different drugs. PF-127 
at concentrations of 20% or higher in aqueous solution 
exhibits the unique property of reversible thermal gelation. 
These preparations transform from low-viscosity solutions 
to semisolid gels upon heating from 4°C to body temperature 
(37°C) and thus can be localized in the injection site with 
minimal distribution of the drug.10 In this capacity, PF-127 
hydrogels have been used as drug delivery vehicles, alone 
and in combination with other delivery systems, to provide 
desirable release profiles.11–14
This kind of depot-like sustained release gel is available 
for many drugs, but there have been no published reports of 
its use for delivery of NTX. Oral NTX is safe and effective 
for the treatment of both alcohol and opioid dependence. 
However, because of its extensive first-pass metabolism, small 
treatment effect, plasma level fluctuations, adverse events, and 
poor patient adherence to the daily dosing schedule, clinical 
acceptance of this dosage form has been limited.15–17 Injectable 
sustained-release preparations of NTX can overcome these 
problems and improve the treatment outcome.18–20
Due to the high solubility of NTX (65 mg/mL) and the 
amphiphilic nature of PF-127, it appears that drug release 
from the carrier may be rapid and characterized by a strong 
burst of drug release.21 Therefore, the effects of formulation 
variables, such as concentration of polymer, pH, and inor-
ganic salts on in vitro drug release were investigated. For 
optimizing the sustained-release pattern, cyclodextrin com-
plexes were also evaluated. Bioadaptable and multifunctional 
cyclodextrin molecules are able to alleviate the undesirable 
properties of drugs given by various routes of administration 
via formation of inclusion complexes.
Hydrophobic cyclodextrins, such as triacetyl-β-cyclodextrin 
(TaβCD, Figure 1), could serve as novel slow-release carriers 
of water soluble drugs, and a combination of molecular encap-
sulation and other carrier materials will become an effective 
and valuable tool in the improvement of drug formulation.22
The most common preparation method for complexes 
with hydrophobic cyclodextrins is the kneading technique.23 
Thus, the binary systems of NTX/TAβCD in different molar 
ratios were prepared by the kneading method, and the release 
behavior of the drug was investigated.
To confirm the formation of a NTX/TAβCD complex, each 
sample was analyzed by differential scanning calorimetry.
Materials and methods
Materials
NTX, PF-127, and TAβCD were purchased from Sigma-Aldrich 
(Schrelldorf, Germany). Analytical grade ethanol and 
inorganic salts were obtained from Merck (Darmstadt, 
Germany). Cellulose acetate membrane (molecular weight 
cutoff 12,000 Da) was obtained from Sigma (Germany). All 
other chemical reagents used were of pharmaceutical grade.
Preparation of nTX PF-127 hydrogel 
formulation
The PF-127 solutions were prepared by the cold method.20 
A weighed amount of PF-127 was slowly added to a cold 
aqueous solution (5–10°C) with gentle mixing until complete 
dissolution of the polymer. The solutions used included a 
phosphate-buffered solution of the polymer at different pH 
values. When inorganic salts (NaCl, Na2SO4, Na2HPO4) were 
used, they were dissolved in distilled water. The polymer was 
then slowly added to the cold water as described.
An appropriate amount of NTX (10 mg/mL) was added 
to each formulation. All gels were kept overnight at 4°C until 
a homogenous solution was obtained.
Preparation of nTX/TAβcD  
inclusion complexes
The binary system of NTX/TAβCD in different molar ratios 
(1:1, 1:2, and 1:4) was prepared by the kneading method, ie, 
TAβCD was wetted in a ceramic mortar with ethanol:water 
50% (v/v) solution until a paste was obtained. The required 
amount of NTX was then added slowly whilst grinding, and 
the slurry was kneaded for about 45 minutes. During this pro-
cess, an appropriate quantity of solvent was added in order to 
maintain a suitable consistency. The product was then dried at 
40°C over 24 hours and added to the poloxamer solution.
Differential scanning calorimetry
The optimum NTX/TAβCD complex was characterized by 
thermal analysis, performed using a differential scanning 
calorimeter (DSC-60, Shimadzu Co., Kyoto, Japan). Thermo-
grams of the different samples (inclusion complex, physical 
mixture, and pure substances) were obtained from differential 
scanning calorimetry equipped with a thermal analysis data 
system. Weighted samples (6–8 mg) were contained in sealed 
aluminum pans and scanned at a rate of 10°C/min, between 
0°C and 300°C, using nitrogen as a purging gas. The ther-
mal analysis was carried out over 300°C during preliminary 
runs, but only thermal events observed over 240°C involved 
decomposition of the materials.
in vitro release studies
In this study, diffusion cells were used to evaluate NTX 
release from the poloxamer hydrogels.21 The diffusion cells Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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are comprised of two compartments separated by a cellulose 
acetate membrane (cutoff 12,000 Da), which does not consti-
tute a barrier against NTX diffusion. The donor compartment 
was filled with 1 mL of formulation, and the receiver compart-
ment was filled with pH 7.4 phosphate buffer (30 mL). Tem-
perature was maintained at 37°C for all experiments. At the 
specified time, aliquots (500 µL) of medium on the receiver 
side were taken and replaced with an equal volume of fresh 
phosphate buffer, in order to maintain sink conditions. The 
collected samples were analyzed by ultraviolet spectroscopy 
at 281 nm. Each experiment was performed in triplicate.
effect of formulation factors on in vitro 
release of nTX from PF-127 gel
effect of PF-127 concentration on drug release
Phosphate-buffered solutions (pH 7.4) containing different 
concentrations of PF-127 (20%, 25%, 30%, and 35% [w/v]) 
without any additive were prepared as described above. The 
in vitro release of NTX from these gel formulations was 
studied.
effect of ph of polymeric solutions on drug release
The effect of pH on drug release was studied using 25% (w/v) 
PF-127 gels. These formulations were prepared in different pH 
solutions, ie, 5.5, 7.4, and 8.5, using 0.2 M phosphate buffer.
effect of inorganic salts on drug release
The effect of salts was studied using 25% Pluronic formula-
tions of NTX in the presence of NaCl, Na2SO4, and Na2HPO4 
(1% w/v). The PF-127 gel formulation with no additive was 
used as a control.
effect of complexation of nTX with  
TAβcD on drug release
The effect of TAβCD was studied using a gel containing 
PF-127 25% (w/v) and binary systems of NTX/TAβCD in 
different molar ratios which were prepared by the kneading 
method. The PF-127 gel formulation with no additive was 
used as a control.
Results and discussion
effect of PF-127 concentration  
on drug release
The effect of PF-127 concentration (20%, 25%, 30%, 
and 35%) on drug release at 37°C is shown in Figure 2. It is 
apparent that the drug release rate decreases as the PF-127 
concentration increases. Increasing the concentration of 
PF-127 from 20% (w/v) to 35% (w/v) decreased the cumula-
tive percent drug released after eight hours from 80% to 50%. 
As shown in Figure 2, the highest concentration of PF-127 
could sustain NTX release at about 55% in 10 hours and 
70% in 48 hours, which is away from our desirable sustained 
profile release.
A hydration layer surrounds PF-127 molecules at low 
temperatures in aqueous solution. However, when the tem-
perature is raised, the hydrophilic chains of the copolymer 
become desolvated as a result of the breakage of the hydro-
gen bonds that had been established between the solvent 
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and these chains. This phenomenon favors hydrophobic 
interactions among the poly oxypropylene domains, lead-
ing to increased chain entanglement and gel formation.22 
This entanglement is more marked at higher concentrations 
of PF-127, yielding an increase in gel strength and conse-
quently a decrease of the drug release rate.27 We should 
mention that 30% and 35% PF-127 hydrogels were very 
viscous and have very low syringability, so are not suitable 
vehicles for subcutaneous injection, so 25% PF-127 which 
has similar release pattern (P . 0.05) was selected for the 
next experiments.
effect of polymeric solution ph  
on drug release
The effect of pH on NTX release was studied at vehicle pH 
values of 5.5, 7.4, and 8.5 using 25% PF-127 phosphate-
buffered solutions (Figure 3). The results showed that pH 5.5 
and 8.5 produced faster release of NTX among the studied 
formulations. This indicates that when the pH of polymeric 
solution is lower or higher than 7.4, diffusion of NTX is 
increased. It may be concluded that ionization of hydroxyl 
groups of polyethylene blocks could increase interchain 
movement and presence of hydronium or hydroxide ions 
between these chains, and have effective roles in polymeric 
chain distance and easier diffusion of drug molecules.
effect of inorganic salts on drug release
Most pharmaceutical PF-127 gels are formulated with salts, 
either for buffering or ionic strength adjustment.28 It has been 
shown that the diffusion of drugs within the gel network 
is significantly affected by salts. We have examined the 
effect of NaCl, Na2SO4, and Na2HPO4 (1% w/v) on drug 
release from PF-127 gels (Figure 4). The results showed 
no significant effect of any of the salts on drug release 
rate (Figure 3). This is very different from earlier results 
where the same salts were shown to decrease diffusion of 
propranolol across a membrane from F127 gels containing 
salts.29 We believe that this discrepancy can be explained 
as follows. The water structure causes salts to reduce the 
critical micelle concentration and temperature of PF-127, 
make the poly(ethylene oxide)-poly(ethylene oxide) chain 
interactions stronger due to a decrease in hydrogen bonding 
with water, and thus make the poly(ethylene oxide) chain 
network tighter. Although the inclusion of salts results in a 
tighter micelle network, it also increases the water uptake 
rate into the gel due to an osmotic effect.30 The net result is 
that salts do not have a measurable effect on drug release 
rate in prepared NTX hydrogel.
effect of TAβcD complex  
on drug release
The release profiles of NTX and NTX/TAβCD binary systems 
in different molar ratios incorporated into 25% w/v PF-127 
formulations are presented in Figure 5. The data show that 
hydrophobic TAβCD slows the release rate, and this effect 
is dependent on the amount of TAβCD in the matrices. 
Cumulative release of the drug after 48 hours approached 85% 
for PF-127 hydrogel alone, compared with less than 60% in 
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Figure 3 In vitro release profiles of naltrexone from 25% PF-127 hydrogel formulations prepared in different pH solutions. Each point represents the mean ± standard 
deviation (n = 3).
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Figure 4 Effect of inorganic salts addition on release of naltrexone from 25% PF-127 hydrogel. Each point represents the mean ± standard deviation (n = 3).
a gel containing1:4 NTX/TAβCD complex. This retardation 
of the drug release rate with TAβCD may be attributed to 
formation of complexes in the kneaded product.
Problems in controlling drug release from polymeric 
carriers are common, particularly for matrices composed of 
hydrophilic polymers, eg, PF-127 hydrogels. In such cases, 
drug release from the carrier may be rapid and characterized 
by a burst release.21 Narasimhan and Langer31 showed that 
burst release was controlled by the solubility of drug, the 
drug diffusion coefficient and the initial drug distributions 
within the polymeric carrier. Retarded drug release, through 
a dissolution-limited mechanism, is a common objective 
for the use of many poorly water-soluble cyclodextrin 
complexes.32
Poorly water-soluble alkylated cyclodextrin derivatives, 
such as TaβCD, are useful as slow-release carriers for water 
soluble drugs.33,34 Furthermore, the incorporation of these 
agents into polymeric drug delivery systems frequently 
permits a greater degree of controlled drug release rate 
and time.35
TAβCD forms noncovalent and poorly water soluble 
complexes with NTX and reduced drug solubility in aqueous 
medium and total concentration of diffusible species, 
resulting in a retarded release. In vitro release experiments   Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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showed that the formulations containing drug/TAβCD in 
molar ratios of 1:2 and 1:4 with no significant difference 
were able to prolong and control NTX release for more than 
144 hours. The optimum formulation showed more than 
three-week stability at refrigerator temperature and 72 hours 
at 37°C.
Differential scanning calorimetry
The solid binary systems were analyzed by means of 
differential scanning calorimetry to detect possible altered 
thermal properties with regard to the pure substances. When 
guest molecules are incorporated in the TAβCD cavity, their 
melting, boiling, and sublimation points generally shift to a 
different temperature or disappear at the temperature range 
within which the cyclodextrin lattice is decomposed.36 The 
differential scanning calorimetry curves for NTX, TaβCD, 
and respective drug-carrier combinations in a molar ratio 
of 1:2 are shown in Figure 6. The thermal curve of NTX 
indicated a mixture of amorphous states and a character-
istic broad endothermic peak at 85.19°C. The TAβCD 
thermogram displayed an endothermic peak at 190.77°C 
due to the fusion process of this crystalline molecule. The 
appearance of two endothermic peaks corresponding to the 
fusion of both components was also evident in the thermo-
gram of the physical mixture, as if this differential scanning 
calorimetry curve was the superimposition of those for the 
components analyzed separately. The shape of the NTX 
melting peak was unaffected by blending with TAβCD, and 
hence the drug maintained its original amorphous state in the 
physical mixture. The complete disappearance of the drug 
endothermic peak was found in the kneaded preparation. 
The absence of the NTX fusion peak indicated the existence 
of interactions between drug and TAβCD in the solid state, 
and could be considered as an indication for the formation 
of real inclusion complexes. The sustained release of drug 
from the hydrogel containing NTX/TAβCD binary system 
supports this theory.
Conclusion
For a novel drug delivery system, one of the major advantages 
is extending product life through formulation, and decreasing 
the number of times that a product is administered. Several 
approaches have been used to improve the prolonged release 
dosage forms to increase patient compliance. One of these 
approaches is the utilization of Pluronic F-127 hydrogels. 
In this study, we developed a new sustained release and 
thermoresponsive drug delivery system for a potent opioid 
receptor antagonist, NTX, to be administrated subcutaneously. 
Poloxamer hydrogel formulations containing NTX were evalu-
ated by in vitro experiments. The results showed that the release 
of NTX from PF-127 hydrogel was affected by formulation 
variables of the gel. Increasing F127 concentration in the gel 
decreases drug release rate. The pH of the polymeric solution 
is also an important factor for NTX release. The addition of 
inorganic salts has no significant effect on drug release. The 
present results suggested that a combination of TAβCD/drug 
complexes and Pluronic gels with sustained-release behavior 
for more than 144 hours is useful for the controlled release of 
a water-soluble drug, and the release rate may be controlled 
by adjusting the molar ratio of the components.
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